Immunocore Holdings plc Shareholders' Equity
Immunocore Holdings plc (IMCR) had Shareholders' Equity of $419.80 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity Attributable to Parent $419.80M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $393.67M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $381.03M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $396.56M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $419.80M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $393.67M 10-Q · filed 2026-08-06 |
| 2025-12-31 | $381.03M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $396.56M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $388.48M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $378.48M 10-Q · filed 2026-08-06 |
| 2024-12-31 | $360.72M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $377.83M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $359.14M 10-Q · filed 2025-11-06 |
| 2024-03-31 | $359.53M 10-Q · filed 2025-11-06 |
| 2023-12-31 | $368.84M 10-K · filed 2026-02-25 |
| 2023-09-30 | $355.97M 10-Q · filed 2024-11-06 |
| 2023-06-30 | $351.44M 10-Q · filed 2024-11-06 |
| 2023-03-31 | $341.30M 10-Q · filed 2024-11-06 |
| 2022-12-31 | $338.90M 10-K · filed 2026-02-25 |
| 2021-12-31 | $233.71M 10-K · filed 2025-02-26 |
| 2020-12-31 | $76.91M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |